BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 17203358)

  • 1. The spectrum of Vogt-Koyanagi-Harada disease in Tunisia, North Africa.
    Khairallah M; Zaouali S; Messaoud R; Chaabane S; Attia S; Ben Yahia S; Hmidi K
    Int Ophthalmol; 2007; 27(2-3):125-30. PubMed ID: 17203358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The spectrum of Vogt-Koyanagi-Harada disease in Turkey: VKH in Turkey.
    Tugal-Tutkun I; Ozyazgan Y; Akova YA; Sullu Y; Akyol N; Soylu M; Kazokoglu H
    Int Ophthalmol; 2007; 27(2-3):117-23. PubMed ID: 16957877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pattern of uveitis in Behçet's disease in a referral center in Tunisia, North Africa.
    Khairallah M; Attia S; Yahia SB; Jenzeri S; Ghrissi R; Jelliti B; Zaouali S; Messaoud R
    Int Ophthalmol; 2009 Jun; 29(3):135-41. PubMed ID: 18365145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The spectrum of Vogt-Koyanagi-Harada disease in Iran.
    Hedayatfar A; Hosseini SM; Karimi N; Falavarjani KG; Badie N; Zameni M; Soheilian M
    Int Ophthalmol; 2018 Apr; 38(2):443-449. PubMed ID: 28260142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pattern of uveitis in a referral centre in Tunisia, North Africa.
    Khairallah M; Yahia SB; Ladjimi A; Messaoud R; Zaouali S; Attia S; Jenzeri S; Jelliti B
    Eye (Lond); 2007 Jan; 21(1):33-9. PubMed ID: 16215541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The spectrum of Vogt-Koyanagi-Harada disease in South India.
    Murthy SI; Moreker MR; Sangwan VS; Khanna RC; Tejwani S
    Int Ophthalmol; 2007; 27(2-3):131-6. PubMed ID: 17318321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in Vogt-Koyanagi-Harada disease.
    Al-Kharashi AS; Aldibhi H; Al-Fraykh H; Kangave D; Abu El-Asrar AM
    Int Ophthalmol; 2007; 27(2-3):201-10. PubMed ID: 17435968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Relationship of Vogt-Koyanagi-Harada Syndrome to Ocular Hypertension and Glaucoma.
    Veerappan M; Fleischman D; Ulrich JN; Stinnett SS; Jaffe GJ; Allingham RR
    Ocul Immunol Inflamm; 2017 Dec; 25(6):748-752. PubMed ID: 27438521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corticotherapy vs. Corticotherapy Plus Immunosuppressive Therapy in Acute Vogt-Koyanagi-Harada Disease.
    Concha-Del Río LE; Gómez L; Arellanes-García L
    Arch Soc Esp Oftalmol (Engl Ed); 2018 May; 93(5):225-230. PubMed ID: 29258782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vogt-Koyanagi-Harada Syndrome in Brazilian Children.
    Marquezan MC; Nascimento H; Dalbem D; Muccioli C; Belfort R
    Ocul Immunol Inflamm; 2020 Apr; 28(3):402-408. PubMed ID: 31120768
    [No Abstract]   [Full Text] [Related]  

  • 11. Vogt-Koyanagi-Harada Syndrome in a Canadian First Nations Population.
    Kryshtalskyj MT; Roy M
    Ocul Immunol Inflamm; 2022 May; 30(4):894-900. PubMed ID: 33621146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vogt-Koyanagi-Harada disease in Spain.
    Arriola-Villalobos P; Moll-Udina A; Carrasco-López-Brea M; Sacristan C; Capella MJ; Peiteado D; Garrote-Llordén A; Albert Fort M; Jódar Márquez M; Jacobo Gonzalez Guijarro J; Demetrio-Pablo R; Luis Sánchez Sevilla J; Carreño E; González-López J; Miguel-Escuder L; Cuadros C; Díaz-Valle D; Adan A; ; Benítez Del Castillo JM; Fonollosa A; Cordero M; Martínez Costa L; Blanco-Alonso R
    Eur J Ophthalmol; 2022 May; 32(3):1547-1554. PubMed ID: 34269103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of 87 cases with Vogt-Koyanagi-Harada disease.
    Mondkar SV; Biswas J; Ganesh SK
    Jpn J Ophthalmol; 2000; 44(3):296-301. PubMed ID: 10913650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vogt-Koyanagi-Harada disease presenting as acute angle closure glaucoma at onset.
    Yang P; Liu X; Zhou H; Guo W; Zhou C; Kijlstra A
    Clin Exp Ophthalmol; 2011; 39(7):639-47. PubMed ID: 22452682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease.
    Abu El-Asrar AM; Hemachandran S; Al-Mezaine HS; Kangave D; Al-Muammar AM
    Acta Ophthalmol; 2012 Dec; 90(8):e603-8. PubMed ID: 22971163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vogt-Koyanagi-Harada disease in Thai patients.
    Tesavibul N; Sansanayuth W
    J Med Assoc Thai; 2005 Nov; 88 Suppl 9():S26-30. PubMed ID: 16681048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vogt-Koyanagi-Harada Disease: The Clinical Spectrum and Management of Case Series in a Tertiary Eye Centre in Northern Part Of Malaysia.
    Hasan AN; Mustapha M; Wan HAHW
    Cesk Slov Oftalmol; 2024; 80(3):140-144. PubMed ID: 38413229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors for Vogt-Koyanagi-Harada disease.
    Sheu SJ; Kou HK; Chen JF
    J Chin Med Assoc; 2003 Mar; 66(3):148-54. PubMed ID: 12779034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vogt-Koyanagi-Harada disease in Hispanic patients.
    Sukavatcharin S; Tsai JH; Rao NA
    Int Ophthalmol; 2007; 27(2-3):143-8. PubMed ID: 17380271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids.
    Nakayama M; Keino H; Watanabe T; Okada AA
    Br J Ophthalmol; 2019 Feb; 103(2):274-278. PubMed ID: 29666121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.